AXQ Capital LP Purchases Shares of 1,644 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

AXQ Capital LP purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,644 shares of the biopharmaceutical company’s stock, valued at approximately $387,000.

A number of other large investors also recently bought and sold shares of ALNY. Larson Financial Group LLC increased its position in shares of Alnylam Pharmaceuticals by 187.2% in the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 73 shares in the last quarter. R Squared Ltd purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $33,000. OFI Invest Asset Management purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $35,000. True Wealth Design LLC increased its position in shares of Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 153 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $45,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock opened at $283.34 on Monday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The business’s fifty day simple moving average is $257.16 and its 200-day simple moving average is $259.74. The firm has a market cap of $36.68 billion, a PE ratio of -130.57 and a beta of 0.39. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Buying and Selling

In related news, CMO Pushkal Garg sold 52,592 shares of the stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the transaction, the chief marketing officer now owns 11,989 shares of the company’s stock, valued at approximately $3,416,865. This represents a 81.44 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Phillip A. Sharp sold 11,250 shares of the stock in a transaction dated Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 71,234 shares of company stock valued at $19,958,097. Corporate insiders own 1.50% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on ALNY shares. Needham & Company LLC restated a “buy” rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday. Sanford C. Bernstein dropped their price target on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. Bank of America boosted their price target on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a “buy” rating in a research report on Friday. Chardan Capital reiterated a “buy” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday. Finally, JPMorgan Chase & Co. boosted their price target on Alnylam Pharmaceuticals from $272.00 to $280.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $310.22.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.